Anders Karlén

Anders Karlén

Auto-generated profile, based on publicly available information

Anders Karlén

Department of Medicinal Chemistry, Organic Pharmaceutical Chemistry, BMC, Uppsala University, Box 574, SE-751 23 Uppsala, Sweden

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2019 in Nature Reviews Microbiology
Verified
Journal Article
Open access
PDF file
UTUrsula Theuretzbacher
Ursula Theuretzbacher
KOKevin Outterson
Kevin Outterson
AEAleks Engel
Aleks Engel
AKAnders Karlén
Anders Karlén
Antibacterial resistance is a great concern and requires global action. A critical question is whether enough new antibacterial drugs are being discovered and developed. A review of the clinical antibacterial drug pipeline was recently published, but comprehensive information about the global preclinical pipeline is unavailable. This Review focuses on discovery and preclinical development projects and has found, as of 1 May 2019, 407 antibacterial projects from 314 institutions. The focus is on Gram-negative pathogens, particularly bacteria on the WHO priority bacteria list. The preclinical pipeline is characterized by high levels of diversity and interesting scientific concepts, with 135 projects on direct-acting small molecules that represent new classes, new targets or new mechanisms of action. There is also a strong trend towards non-traditional approaches, including diverse antivirulence approaches, microbiome-modifying strategies, and engineered phages and probiotics. The high number of pathogen-specific and adjunctive approaches is unprecedented in antibiotic history. Translational hurdles are not adequately addressed yet, especially development pathways to show clinical impact of non-traditional approaches. The innovative potential of the preclinical pipeline compared with the clinical pipeline is encouraging but fragile. Much more work, focus and funding are needed for the novel approaches to result in effective antibacterial therapies to sustainably combat antibacterial resistance.

13 September 2002 in Journal of Molecular Graphics and Modelling
Verified
Journal Article
Closed access
SWSusanne Winiwarter
Susanne Winiwarter
FAFredrik Ax
Fredrik Ax
HLHans Lennernäs
Hans Lennernäs
AHAnders Hallberg
Anders Hallberg
CPCurt Pettersson
Curt Pettersson
AKAnders Karlén
Anders Karlén

2 February 2017 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
HAHiba Alogheli
Hiba Alogheli
GOGustav Olanders
Gustav Olanders
WSWesley Schaal
Wesley Schaal
PBPeter Brandt
Peter Brandt
AKAnders Karlén
Anders Karlén
In recent years, there has been an increased interest in using macrocyclic compounds for drug discovery and development. For docking of these commonly large and flexible compounds to be addressed, a screening and a validation set were assembled from the PDB consisting of 16 and 31 macrocycle-containing protein complexes, respectively. The macrocycles were docked in Glide by rigid docking of pregenerated conformational ensembles produced by the macrocycle conformational sampling method (MCS) in Schrödinger Release 2015-3 or by direct Glide flexible docking after performing ring-templating. The two protocols were compared to rigid docking of pregenerated conformational ensembles produced by an exhaustive Monte Carlo multiple minimum (MCMM) conformational search and a shorter MCMM conformational search (MCMM-short). The docking accuracy was evaluated and expressed as the RMSD between the heavy atoms of the ligand as found in the X-ray structure after refinement and the poses obtained by the docking protocols. The median RMSD values for top-scored poses of the screening set were 0.83, 0.80, 0.88, and 0.58 Å for MCMM, MCMM-short, MCS, and Glide flexible docking, respectively. There was no statistically significant difference in the performance between rigid docking of pregenerated conformations produced by the MCS and direct docking using Glide flexible docking. However, the flexible docking protocol was 2-times faster in docking the screening set compared to that of the MCS protocol. In a final study, the new Prime-MCS method was evaluated in Schrödinger Release 2016-3. This method is faster compared that of to MCS; however, the conformations generated were found to be suboptimal for rigid docking. Therefore, on the basis of timing, accuracy, and ease of set up, standard Glide flexible docking with prior ring-templating is recommended over current gold standard protocols using rigid docking of pregenerated conformational ensembles.

8 March 2012 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
JGJohan Gising
Johan Gising
MNMikael T. Nilsson
Mikael T. Nilsson
LOLuke R. Odell
Luke R. Odell
SYSamir Yahiaoui
Samir Yahiaoui
MLMartin Lindh
Martin Lindh
AKAnders Karlén
Anders Karlén
Mycobacterium tuberculosis glutamine synthetase (MtGS) is a promising target for antituberculosis drug discovery. In a recent high-throughput screening study we identified several classes of MtGS inhibitors targeting the ATP-binding site. We now explore one of these classes, the 2-tert-butyl-4,5-diarylimidazoles, and present the design, synthesis, and X-ray crystallographic studies leading to the identification of MtGS inhibitors with submicromolar IC50 values and promising antituberculosis MIC values.

11 September 2006 in Journal of Peptide Science
Verified
Journal Article
Closed access
PDF file
AAAndreas Axén
Andreas Axén
GLGunnar Lindeberg
Gunnar Lindeberg
HDHeidi Demaegdt
Heidi Demaegdt
GVGeorges Vauquelin
Georges Vauquelin
AKAnders Karlén
Anders Karlén
MHMathias Hallberg
Mathias Hallberg

12 March 2012 in MedChemComm
Verified
Journal Article
Closed access
PDF file
ANAnneli Nordqvist
Anneli Nordqvist
MNMikael T. Nilsson
Mikael T. Nilsson
OLOlof Lagerlund
Olof Lagerlund
DMDaniel Muthas
Daniel Muthas
JGJohan Gising
Johan Gising
AKAnders Karlén
Anders Karlén
Based on an imidazo[1,2-a]pyridine hit from a high-throughput screening directed at the M. tuberculosis enzyme glutamine synthetase, a hit expansion was performed by synthesizing a number of analogs. A set of 16 molecules was first synthesized according to a statistical molecular design approach. One potent inhibitor was identified (IC50 = 3.0 μM), which led to the synthesis of 17 additional imidazo[1,2-a]pyridines in a follow-up study. Among these, several inhibitors were identified with single-digit micromolar potency and one with sub-micromolar potency. An X-ray structure of one of these revealed the binding mode of this class of inhibitors in the ATP-binding site, and allowed us to rationalize many of the structure–activity relationships observed.